Skip to main content
Erschienen in: Tumor Biology 2/2011

01.04.2011 | Research Article

Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients

verfasst von: Sarfraz Ali, Qiqin Yin-Goen, Timothy V. Johnson, Wei Han, Nicole A. Johnson, Wayne B. Harris, Fray F. Marshall, Andrew N. Young, Viraj A. Master, Adeboye O. Osunkoya

Erschienen in: Tumor Biology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

C-reactive protein is produced in response to cytokines such as interleukin (IL)-6. It is known that increased plasma IL-6 levels induce increased hepatic and intratumoral production of C-reactive protein. Cyclooxygenase enzyme-2 is induced by various stimuli, including inflammation and various growth factors. Expression of these two markers has not been well studied in clear cell renal cell carcinoma. The objective of this study is to correlate the expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma with pathologic parameters. A search of the surgical pathology and consultation files at our institution was performed for nephrectomy specimens with clear cell renal cell carcinoma from 2007 to 2008. Immunohistochemical stains for C-reactive protein and cyclooxygenase enzyme-2 were performed. Staining intensity was graded as 0, 1+, 2+, and 3+. The staining intensity was then correlated with pathologic stage and Fuhrman nuclear grade for each case. A total of 110 cases were identified. Strong expression of C-reactive protein was associated with higher Fuhrman nuclear grade and pathologic stage, and the strength of correlation was statistically significant (p = 0.01 and p = 0.001), respectively. However, cyclooxygenase enzyme-2 expression did not show statistically significant correlation with both pathologic stage and Fuhrman nuclear grade (p = 0.1 and p = 0.15), respectively. To our knowledge, this is the largest study to date correlating the expression of both C-reactive protein and cyclooxygenase enzyme-2 in tissue with pathologic parameters in patients with clear cell renal cell carcinoma, which could have significant prognostic and therapeutic implications.
Literatur
1.
Zurück zum Zitat American Cancer Society. Facts and figures, 2009. American Cancer Society. Facts and figures, 2009.
2.
Zurück zum Zitat Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumors of the urinary system and male genital organs. WHO classification of tumors: IARC Press, Lyon; 2004. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumors of the urinary system and male genital organs. WHO classification of tumors: IARC Press, Lyon; 2004.
3.
Zurück zum Zitat Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.CrossRefPubMed Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.CrossRefPubMed
4.
Zurück zum Zitat Koo AS, Armstrong C, Bochner B, et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992;35:97–105.CrossRefPubMed Koo AS, Armstrong C, Bochner B, et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992;35:97–105.CrossRefPubMed
5.
Zurück zum Zitat Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250:607–10.CrossRefPubMed Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250:607–10.CrossRefPubMed
6.
Zurück zum Zitat Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88:348–53.CrossRefPubMed Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88:348–53.CrossRefPubMed
7.
Zurück zum Zitat Vogl UM, Zehetgruber H, Dominkus M, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95:691–8.CrossRefPubMed Vogl UM, Zehetgruber H, Dominkus M, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95:691–8.CrossRefPubMed
8.
Zurück zum Zitat Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007;99:77–80.CrossRefPubMed Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007;99:77–80.CrossRefPubMed
9.
Zurück zum Zitat Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006;13:1365–70.CrossRefPubMed Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006;13:1365–70.CrossRefPubMed
10.
Zurück zum Zitat Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma specific mortality: a European study of 313 patients. Cancer. 2007;110:1241–7.CrossRefPubMed Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma specific mortality: a European study of 313 patients. Cancer. 2007;110:1241–7.CrossRefPubMed
11.
Zurück zum Zitat Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005;173:52–5.CrossRefPubMed Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005;173:52–5.CrossRefPubMed
12.
Zurück zum Zitat Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007;109:205–12.CrossRefPubMed Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007;109:205–12.CrossRefPubMed
13.
Zurück zum Zitat Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol. 1998;5:418–22.CrossRefPubMed Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol. 1998;5:418–22.CrossRefPubMed
14.
Zurück zum Zitat Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the pre-operative systemic inflammatory response and cancer specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer. 2006;94:781–4.CrossRefPubMed Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the pre-operative systemic inflammatory response and cancer specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer. 2006;94:781–4.CrossRefPubMed
15.
Zurück zum Zitat Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004;30:261–77.CrossRefPubMed Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004;30:261–77.CrossRefPubMed
16.
Zurück zum Zitat Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005;92:651–4.CrossRefPubMed Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005;92:651–4.CrossRefPubMed
17.
Zurück zum Zitat Buckminster F, Mark BE. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–9.CrossRef Buckminster F, Mark BE. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–9.CrossRef
18.
Zurück zum Zitat Hara S, Kondo Y, Matsuzawa I, et al. Expression of cycloxygenase-2 in human bladder and renal cell carcinoma. Adv Exp Med Biol. 2002;507:123–6.PubMed Hara S, Kondo Y, Matsuzawa I, et al. Expression of cycloxygenase-2 in human bladder and renal cell carcinoma. Adv Exp Med Biol. 2002;507:123–6.PubMed
19.
Zurück zum Zitat Miyata Y, Koga S, Kanda S, et al. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res. 2003;9:1741–9.PubMed Miyata Y, Koga S, Kanda S, et al. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res. 2003;9:1741–9.PubMed
20.
Zurück zum Zitat Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431–502.CrossRefPubMed Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431–502.CrossRefPubMed
21.
Zurück zum Zitat Ohtawa Y, Naomoto Y, Shirakawa Y, et al. The close relationship between heparinase and cyclo-oxygenase-2 expressions in signet-ring cell carcinoma of the stomach. Hum Pathol. 2006;37:1145–52.CrossRefPubMed Ohtawa Y, Naomoto Y, Shirakawa Y, et al. The close relationship between heparinase and cyclo-oxygenase-2 expressions in signet-ring cell carcinoma of the stomach. Hum Pathol. 2006;37:1145–52.CrossRefPubMed
22.
Zurück zum Zitat Chen Q, Shinohara N, Abe T, et al. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer. 2004;108:825–32.CrossRefPubMed Chen Q, Shinohara N, Abe T, et al. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer. 2004;108:825–32.CrossRefPubMed
23.
Zurück zum Zitat Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333–8.CrossRefPubMed Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333–8.CrossRefPubMed
24.
Zurück zum Zitat Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4064–8.PubMed Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4064–8.PubMed
25.
Zurück zum Zitat Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z. Significance of COX-2 expression in human renal cell carcinoma. Urology. 2004;64:1116–20.CrossRefPubMed Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z. Significance of COX-2 expression in human renal cell carcinoma. Urology. 2004;64:1116–20.CrossRefPubMed
26.
Zurück zum Zitat Ramsey S, Lamb GW, Aitchison M, et al. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008;101:959.CrossRefPubMed Ramsey S, Lamb GW, Aitchison M, et al. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008;101:959.CrossRefPubMed
27.
Zurück zum Zitat Iimura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009;181:1004.CrossRefPubMed Iimura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009;181:1004.CrossRefPubMed
28.
29.
Zurück zum Zitat Lamb GW, McArdle PA, Ramsey S, et al. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008;102:756.CrossRefPubMed Lamb GW, McArdle PA, Ramsey S, et al. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008;102:756.CrossRefPubMed
30.
Zurück zum Zitat Jabs WJ, Busse M, Kurger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005;68:2103.CrossRefPubMed Jabs WJ, Busse M, Kurger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005;68:2103.CrossRefPubMed
31.
Zurück zum Zitat Canna K, McMillan DC, McKee RF, et al. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer. 2004;90:1707.PubMed Canna K, McMillan DC, McKee RF, et al. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer. 2004;90:1707.PubMed
32.
Zurück zum Zitat McKeown DJ, Brown DJ, Kelly A, et al. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small cell lung cancer. Br J Cancer. 2004;91:1993.CrossRefPubMed McKeown DJ, Brown DJ, Kelly A, et al. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small cell lung cancer. Br J Cancer. 2004;91:1993.CrossRefPubMed
33.
Zurück zum Zitat Johnson TV, Abbasi A, Owen-Smith A, et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 2010 (in press). Johnson TV, Abbasi A, Owen-Smith A, et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 2010 (in press).
34.
Zurück zum Zitat Jabs WJ, Busse M, Krüger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005;68:2103–10.CrossRefPubMed Jabs WJ, Busse M, Krüger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005;68:2103–10.CrossRefPubMed
35.
Zurück zum Zitat Paule B, Belot J, Rudant C, Coulombel C, Abbou CC. The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol. 2000;53(5):388–90.CrossRefPubMed Paule B, Belot J, Rudant C, Coulombel C, Abbou CC. The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol. 2000;53(5):388–90.CrossRefPubMed
36.
Zurück zum Zitat Costes V, Liautard J, Picot MC, et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol. 1997;50(10):835–40.CrossRefPubMed Costes V, Liautard J, Picot MC, et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol. 1997;50(10):835–40.CrossRefPubMed
37.
Zurück zum Zitat Sun H, Wang H, Qin WJ, Yang B, Wang SC, Jian BL. Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009; 25(4):348–50 (Article in Chinese). Sun H, Wang H, Qin WJ, Yang B, Wang SC, Jian BL. Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009; 25(4):348–50 (Article in Chinese).
38.
Zurück zum Zitat Chang BD, Cao LS, Zhou HL. Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2009; 31(9):687–90. (Article in Chinese). Chang BD, Cao LS, Zhou HL. Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2009; 31(9):687–90. (Article in Chinese).
39.
Zurück zum Zitat Hashimoto Y, Kondo Y, Kimura G, et al. Cyclooxygenase-2 expression and relationship to tumor progression in human renal cell carcinoma. Histopathology. 2004;44:353–9.CrossRefPubMed Hashimoto Y, Kondo Y, Kimura G, et al. Cyclooxygenase-2 expression and relationship to tumor progression in human renal cell carcinoma. Histopathology. 2004;44:353–9.CrossRefPubMed
40.
Zurück zum Zitat Cho DS, Joo HJ, Oh DK, et al. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J. 2005;46:133–40.CrossRefPubMed Cho DS, Joo HJ, Oh DK, et al. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J. 2005;46:133–40.CrossRefPubMed
Metadaten
Titel
Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients
verfasst von
Sarfraz Ali
Qiqin Yin-Goen
Timothy V. Johnson
Wei Han
Nicole A. Johnson
Wayne B. Harris
Fray F. Marshall
Andrew N. Young
Viraj A. Master
Adeboye O. Osunkoya
Publikationsdatum
01.04.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0130-9

Weitere Artikel der Ausgabe 2/2011

Tumor Biology 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.